Related Experiment Video
Updated: Oct 1, 2025

Measuring the Carotid to Femoral Pulse Wave Velocity Cf-PWV to Evaluate Arterial Stiffness
Published on: May 3, 2018
Relationship between Serum FGF21 and vWF Expression and Carotid Atherosclerosis in Elderly Patients with Hypertension
Jing Bian1, Lairong Chen2, Qin Li1
1Department of Cardiovascular Medicine, the Affiliated Hospital of Kangda College of Nanjing Medical University (the First People's Hospital of Lianyungang), Lianyungang 222002, Jiangsu, China.
Insights
Serum FGF21 and vWF levels are elevated in elderly hypertensive patients with carotid atherosclerosis (CAS). These biomarkers can help diagnose CAS and predict cardiovascular and cerebrovascular event risk.
Area of Science:
- Gerontology
- Cardiovascular Medicine
- Biochemistry
Background:
- Cardiovascular (CV) and cerebrovascular (CBV) diseases pose significant risks for the elderly, with hypertension being a major contributing factor.
- Carotid atherosclerosis (CAS) is a common manifestation of CV and CBV disease in hypertensive individuals.
Purpose of the Study:
- To investigate the relationship between serum fibroblast growth factor 21 (FGF21) and von Willebrand factor (vWF) expression and carotid atherosclerosis (CAS) in elderly hypertensive patients.
- To evaluate the diagnostic and prognostic value of FGF21 and vWF in this patient population.
Main Methods:
- Enzyme-linked immunosorbent assay (ELISA) was used to measure serum FGF21 and vWF levels in 143 elderly hypertensive patients (75 with CAS, 68 without).
- Receiver operating characteristic (ROC) curve analysis assessed diagnostic and prognostic capabilities.
- Pearson's correlation analysis examined the relationship between biomarkers and plaque characteristics.
Main Results:
- Serum FGF21 and vWF levels were significantly higher in hypertensive patients with CAS compared to those without.
- Both FGF21 and vWF showed a positive correlation with carotid plaque thickness and stenosis area.
- ROC analysis indicated good diagnostic accuracy for CAS (AUC for FGF21=0.790, vWF=0.807) and prediction of CV/CBV events (AUC for FGF21=0.771, vWF=0.754).
Conclusions:
- Elevated serum FGF21 and vWF levels are associated with the presence of CAS in elderly hypertensive patients.
- These biomarkers demonstrate potential for diagnosing CAS and predicting the risk of future cardiovascular and cerebrovascular events in this demographic.
Abstract:
Cardiovascular (CV) and cerebrovascular (CBV) diseases are common in the elderly and cause severe damage, with high morbidity, disability, and mortality. Hypertension, as a risk factor for a variety of CV and CBV diseases, also affects many elderly patients. This study aimed to investigate the relationship between serum FGF21 and vWF expression and carotid atherosclerosis (CAS) in elderly patients with hypertension. We recruited 143 elderly hypertensive patients admitted to our hospital from July 2017 to November 2019 to this study, including 75 patients with comorbid CAS (the observation group, OG) and 68 patients without CAS (the control group, CG). Enzyme-linked immunosorbent assay (ELISA) was used to test serum expression levels of FGF21 and vWF; receiver operating characteristic (ROC) curves to evaluate the value of FGF21 and vWF in diagnosing CAS and predicting the 6-month prognosis in elderly hypertensive patients; Pearson's correlation analysis to analyze the correlation of FGF21/vWF with the plaque thickness and stenosis area in hypertensive patients with CAS. The incidence of CV and CBV events was markedly higher in the high FGF21/vWF group than in the low FGF21/vWF group. Patients from OG were divided into the high FGF21/vWF group and the low FGF21/vWF group based on the median expression level of FGF21/vWF, then the incidence of cardiovascular (CV) and cerebrovascular (CBV) events was compared between the high and low expression groups. Serum levels of FGF21 and vWF were markedly higher in patients from OG than in patients from CG. Both FGF21 and vWF were in positive correlation with the plaque thickness and stenosis area in patients from OG. The area under the ROC curve (AUC) for diagnosing CAS was 0.790 by FGF21 and 0.807 by vWF; the AUC for predicting the occurrence of CV and CBV events was 0.771 by FGF21 and 0.754 by vWF. Serum levels of FGF21 and vWF are increased in elderly patients with hypertension and comorbid CAS, so they can be used for diagnosing CAS and predicting prognosis.
Related Concept Videos
Hypertension II: Pathophysiology
Hypertension III: Clinical Manifestations and Diagnostic Studies
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Factors affecting Blood pressure
Physiological Factors:
Atherosclerosis III: Management
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

